DTCFF 3.54 Defence Therapeutics Inc.
| Range: | 0.4-2.3 | Vol Avg: | 202 | Last Div: | 0 | Changes: | -0.05 |
| Beta: | 1.45 | Cap: | 0.02B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Tue May 18 2021 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | CA24463V1013 | Country: | CA | ||
| CEO: | Mr. Sebastien Plouffe | Website: | https://defencetherapeutics.com | ||||
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow